Home

Vor Biopharma Inc. - Common Stock (VOR)

1.0452
+0.1552 (17.44%)
NASDAQ · Last Trade: Jun 27th, 10:39 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close0.8900
Open0.9400
Bid1.040
Ask1.050
Day's Range0.9050 - 1.090
52 Week Range0.1311 - 1.800
Volume17,016,446
Market Cap-
PE Ratio (TTM)-
EPS (TTM)-
Dividend & YieldN/A (N/A)
1 Month Average Volume27,660,511

Chart

About Vor Biopharma Inc. - Common Stock (VOR)

Vor Biopharma Inc is a biotechnology company focused on developing innovative therapies for patients with cancer. The company is pioneering a unique approach to create engineered cell therapies that harness the power of the immune system to target and destroy cancer cells more effectively. By utilizing its proprietary platform, Vor Biopharma is working to enhance the safety and efficacy of these treatments, aiming to improve outcomes for patients suffering from various malignancies. The company is dedicated to advancing its research and development efforts to bring new hope and solutions to the oncology landscape. Read More

News & Press Releases

12 Health Care Stocks Moving In Thursday's After-Market Sessionbenzinga.com
Via Benzinga · June 26, 2025
Peraso (NASDAQ: PRSO) Volume Surges on Takeover News – More Stocks Inside
Mobix Labs, Inc. (NASDAQ: MOBX) has launched an unsolicited, non-binding proposal to acquire Peraso Inc. (NASDAQ: PRSO) in a stock-for-stock deal offering Peraso shareholders a 20% premium over the company’s 30-day average share price.
Via AB Newswire · June 26, 2025
Top movers in Thursday's sessionchartmill.com
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 26, 2025
These stocks are the most active in today's sessionchartmill.com
Discover the most active stocks in Thursday's session. Stay informed about the stocks that are generating the most trading volume!
Via Chartmill · June 26, 2025
12 Health Care Stocks Moving In Thursday's Intraday Sessionbenzinga.com
Via Benzinga · June 26, 2025
Which stocks have an unusual volume on Thursday?chartmill.com
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Via Chartmill · June 26, 2025
Here are the top movers in Thursday's session.chartmill.com
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · June 26, 2025
Why This Biotech Stock Just Doubled In A Single Daybenzinga.com
Vor Biopharma shares surge 43% after licensing deal, $175M raise, and CEO transition.
Via Benzinga · June 26, 2025
Gapping stocks in Thursday's sessionchartmill.com
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · June 26, 2025
Dow Surges 200 Points; US GDP Contracts 0.5%benzinga.com
Via Benzinga · June 26, 2025
Thursday's pre-market session: top gainers and loserschartmill.com
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · June 26, 2025
12 Health Care Stocks Moving In Thursday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 26, 2025
Why Worthington Steel Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · June 26, 2025
12 Health Care Stocks Moving In Wednesday's After-Market Sessionbenzinga.com
Via Benzinga · June 25, 2025
Top movers in Wednesday's after hours sessionchartmill.com
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · June 25, 2025
Vor Bio Announces $175 Million Private Placement
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it has entered into a securities purchase agreement for a private placement in public equity financing (the “PIPE”) that is expected to result in gross proceeds of approximately $175 million, before deducting expenses.
By Vor Biopharma · Via GlobeNewswire · June 25, 2025
Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset
-Vor Bio receives ex-Greater China rights to develop and commercialize telitacicept, a novel, dual-target recombinant fusion protein in global Phase 3 development for generalized myasthenia gravis
By Vor Biopharma · Via GlobeNewswire · June 25, 2025
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.chartmill.com
Here are the top movers in Wednesday's session, showcasing the stocks with significant price changes.
Via Chartmill · June 25, 2025
12 Health Care Stocks Moving In Wednesday's Intraday Sessionbenzinga.com
Via Benzinga · June 25, 2025
Let's have a look at the top gainers and losers in the middle of the day of today's session.chartmill.com
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · June 25, 2025
12 Health Care Stocks Moving In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · June 25, 2025
Curious about the most active stocks on Tuesday?chartmill.com
Stay updated with the latest market activity on Tuesday. Explore the most active stocks in today's session and stay informed about the stocks that are in the spotlight.
Via Chartmill · June 24, 2025
What's going on in today's sessionchartmill.com
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via Chartmill · June 23, 2025
12 Health Care Stocks Moving In Monday's Intraday Sessionbenzinga.com
Via Benzinga · June 23, 2025
12 Health Care Stocks Moving In Friday's After-Market Sessionbenzinga.com
Via Benzinga · June 13, 2025